{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T14:46:39Z","timestamp":1773672399933,"version":"3.50.1"},"reference-count":26,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>\n                    Male breast cancer (MBC) is a rare disease, accounting for about 1% of all breast cancer cases worldwide. Compared to female breast cancer (FBC), MBC shows a higher prevalence of hormone receptor positivity and distinct germline predispositions, most frequently pathogenic variants in\n                    <jats:italic>BRCA2<\/jats:italic>\n                    and\n                    <jats:italic>CHEK2<\/jats:italic>\n                    . The contribution of mismatch repair (MMR) genes such as\n                    <jats:italic>MSH6<\/jats:italic>\n                    to MBC risk remains, however, unclear. In addition, polygenic risk scores (PRS) have emerged as promising tools for breast cancer risk prediction but are not yet used in routine care. We report the case of a 42-year-old man diagnosed with invasive carcinoma of no special type, strongly estrogen receptor\u2013positive, HER2-negative, and with a family history of breast and prostate cancer. Genetic testing revealed a pathogenic\n                    <jats:italic>CHEK2<\/jats:italic>\n                    nonsense variant (p.Trp411*), a likely pathogenic\n                    <jats:italic>MSH6<\/jats:italic>\n                    frameshift variant, and a breast cancer PRS in the 99th percentile. Tumor sequencing confirmed both germline variants but showed microsatellite stability and no loss of heterozygosity, arguing against a causal role of\n                    <jats:italic>MSH6<\/jats:italic>\n                    . This case illustrates how PRS, in combination with moderate-risk variants, like those in\n                    <jats:italic>CHEK2<\/jats:italic>\n                    , may drive early-onset MBC and highlights the need to incorporate polygenic models into risk assessment and counseling.\n                  <\/jats:p>","DOI":"10.3389\/fonc.2026.1764722","type":"journal-article","created":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T13:32:49Z","timestamp":1773667969000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Case Report: A combination of CHEK2 and high polygenic risk score leads to early-onset male breast cancer"],"prefix":"10.3389","volume":"16","author":[{"given":"Kamil","family":"Tamindarov","sequence":"first","affiliation":[{"name":"Faculty of Medicine Hospital Carl Gustav Carus, TU Dresden","place":["Dresden, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marika","family":"Frank","sequence":"additional","affiliation":[{"name":"Institute for Clinical Genetics, University Hospital Carl Gustav Carus at TUD Dresden University of Technology and Faculty of Medicine of TUD Dresden University of Technology","place":["Dresden, Germany"]},{"name":"Center for Diagnostics, Human Genetics Department, Chemnitz Clinics","place":["Chemnitz, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sonja","family":"Wegscheider","sequence":"additional","affiliation":[{"name":"Center for Diagnostics, Human Genetics Department, Chemnitz Clinics","place":["Chemnitz, Germany"]},{"name":"Institute of Human Genetics, University of Leipzig Medical Center","place":["Leipzig, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrix","family":"Benedix","sequence":"additional","affiliation":[{"name":"DRK Hospital Chemnitz Rabenstein, Women\u2019s Hospital","place":["Chemnitz, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Lingscheidt","sequence":"additional","affiliation":[{"name":"MVZ Diagnosticum GmbH","place":["Stollberg-Niederdorf, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Neukirchner","sequence":"additional","affiliation":[{"name":"MVZ Diagnosticum GmbH","place":["Stollberg-Niederdorf, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hadeel","family":"Shamma","sequence":"additional","affiliation":[{"name":"Institute for Pathology, Chemnitz Clinics","place":["Chemnitz, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Schnabel","sequence":"additional","affiliation":[{"name":"DRK Hospital Chemnitz Rabenstein, Women\u2019s Hospital","place":["Chemnitz, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Tolkmitt","sequence":"additional","affiliation":[{"name":"DRK Hospital Chemnitz Rabenstein, Women\u2019s Hospital","place":["Chemnitz, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karina","family":"Pillau","sequence":"additional","affiliation":[{"name":"DRK Hospital Chemnitz Rabenstein, Women\u2019s Hospital","place":["Chemnitz, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vincent","family":"Strehlow","sequence":"additional","affiliation":[{"name":"Institute of Human Genetics, University of Leipzig Medical Center","place":["Leipzig, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Hentschel","sequence":"additional","affiliation":[{"name":"Institute of Human Genetics, University of Leipzig Medical Center","place":["Leipzig, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Le Duc","sequence":"additional","affiliation":[{"name":"Institute for Clinical Genetics, University Hospital Carl Gustav Carus at TUD Dresden University of Technology and Faculty of Medicine of TUD Dresden University of Technology","place":["Dresden, Germany"]},{"name":"Center for Diagnostics, Human Genetics Department, Chemnitz Clinics","place":["Chemnitz, Germany"]},{"name":"Institute of Human Genetics, University of Leipzig Medical Center","place":["Leipzig, Germany"]},{"name":"ERN GENTURIS, Hereditary Cancer Syndrome Center Dresden","place":["Dresden, Germany"]},{"name":"National Center for Tumor Diseases (NCT), NCT\/UCC Dresden, a partnership between DKFZ, Faculty of Medicine and University Hospital Carl Gustav Carus, TUD Dresden University of Technology, and Helmholtz-Zentrum Dresden-Rossendorf (HZDR)","place":["Dresden, Germany"]},{"name":"German Cancer Consortium (DKTK), partner site: Dresden, and German Cancer Research Center (DKFZ)","place":["Heidelberg, Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1707939","article-title":"Breast cancer in men. Longo DL, herausgeber","volume":"378","author":"Giordano","year":"2018","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1007\/s00428-021-03190-7","article-title":"Male breast cancer: an update","volume":"480","author":"Fox","year":"2022","journal-title":"Virchows Arch"},{"key":"B3","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13058-024-01872-z","article-title":"Genomic profiling and comparative analysis of male versus female metastatic breast cancer across subtypes","volume":"26","author":"Kadamkulam Syriac","year":"2024","journal-title":"Breast Cancer Res"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2016.02.017","article-title":"Male breast cancer is not congruent with the female disease","volume":"101","author":"Fentiman","year":"2016","journal-title":"Crit Rev Oncology\/Hematology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1414343","article-title":"BRCA-associated hereditary male cancers: can gender affect the prevalence and spectrum of germline pathogenic variants","volume":"14","author":"Fanale","year":"2024","journal-title":"Front Oncol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"100870","DOI":"10.1016\/j.gim.2023.100870","article-title":"Management of individuals with germline pathogenic\/likely pathogenic variants in CHEK2: A clinical practice resource of the American College of Medical Genetics and Genomics (ACMG)","volume":"25","author":"Hanson","year":"2023","journal-title":"Genet Med"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1136\/jmg-2023-109826","article-title":"Pathogenic variant detection rate varies considerably in male breast cancer families and sporadic cases: minimal additional contribution beyond BRCA2, BRCA1 and CHEK2","volume":"61","author":"Evans","year":"2024","journal-title":"J Med Genet"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1913948","article-title":"Breast cancer risk genes - association analysis in more than 113,000 women","volume":"384","author":"Dorling","year":"2021","journal-title":"N Engl J Med 4. Februar"},{"key":"B9","article-title":"CHEK2-related cancer predisposition","volume-title":"Herausgeber. GeneReviews","author":"Hanson","year":"2025"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-21-2027","article-title":"Morphologic and genomic characteristics of breast cancers occurring in individuals with lynch syndrome","volume":"28","author":"Schwartz","year":"2022","journal-title":"Clin Cancer Res"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djad063","article-title":"Microsatellite instability in noncolorectal and nonendometrial Malignancies in patients with Lynch syndrome","volume":"115","author":"Elze","year":"2023","journal-title":"JNCI: J Natl Cancer Institute"},{"key":"B12","doi-asserted-by":"publisher","first-page":"14348","DOI":"10.3390\/ijms241814348","article-title":"Multigene panel sequencing identifies a novel germline mutation profile in male breast cancer patients","volume":"24","author":"Al Saati","year":"2023","journal-title":"IJMS"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-021-06413-2","article-title":"Penetrance of male breast cancer susceptibility genes: a systematic review","volume":"191","author":"Chamseddine","year":"2022","journal-title":"Breast Cancer Res Treat"},{"key":"B14","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.ajhg.2018.11.002","article-title":"Polygenic risk scores for prediction of breast cancer and breast cancer subtypes","volume":"104","author":"Mavaddat","year":"2019","journal-title":"Am J Hum Genet"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaa101","article-title":"Common susceptibility loci for male breast cancer","volume":"113","author":"Maguire","year":"2021","journal-title":"JNCI: J Natl Cancer Institute"},{"key":"B16","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s10549-021-06159-x","article-title":"Male and female breast cancer: the two faces of the same genetic susceptibility coin","volume":"188","author":"Silva","year":"2021","journal-title":"Breast Cancer Res Treat"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djab147","article-title":"Breast and prostate cancer risks for male BRCA1 and BRCA2 pathogenic variant carriers using polygenic risk scores","volume":"114","author":"Barnes","year":"2022","journal-title":"JNCI: J Natl Cancer Institute"},{"key":"B18","doi-asserted-by":"publisher","first-page":"3635","DOI":"10.1038\/s41467-020-17374-3","article-title":"Polygenic background modifies penetrance of monogenic variants for tier 1 genomic conditions","volume":"11","author":"Fahed","year":"2020","journal-title":"Nat Commun"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.7326\/M20-5874","article-title":"Cases in precision medicine: the role of polygenic risk scores in breast cancer risk assessment","volume":"174","author":"Zeinomar","year":"2021","journal-title":"Ann Intern Med"},{"key":"B20","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/j.jaci.2019.09.009","article-title":"Diagnostic interpretation of genetic studies in patients with primary immunodeficiency diseases: A working group report of the Primary Immunodeficiency Diseases Committee of the American Academy of Allergy, Asthma & Immunology","volume":"145","author":"Chinn","year":"2020","journal-title":"J Allergy Clin Immunol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1086\/337944","article-title":"Molecular and clinical characteristics of MSH6 variants: an analysis of 25 index carriers of a germline variant","volume":"70","author":"Berends","year":"2002","journal-title":"Am J Hum Genet"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1038\/s41431-024-01647-2","article-title":"Limitations in next-generation sequencing-based genotyping of breast cancer polygenic risk score loci","volume":"32","author":"Baumann","year":"2024","journal-title":"Eur J Hum Genet"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.21873\/anticanres.16086","article-title":"Genetic predisposition to male breast cancer: A case series","volume":"42","author":"Apessos","year":"2022","journal-title":"Anticancer Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1136\/jmg-2023-109791","article-title":"Estimating cancer risk in carriers of Lynch syndrome variants in UK Biobank","volume":"61","author":"Fummey","year":"2024","journal-title":"J Med Genet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1038\/s41436-019-0596-9","article-title":"Cancer risks by gene, age, and gender in 6350 carriers of pathogenic mismatch repair variants: findings from the Prospective Lynch Syndrome Database","volume":"22","author":"Dominguez-Valentin","year":"2020","journal-title":"Genet Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1038\/gim.2017.254","article-title":"MSH6 and PMS2 germ-line pathogenic variants implicated in Lynch syndrome are associated with breast cancer","volume":"20","author":"Roberts","year":"2018","journal-title":"Genet Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1764722\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T13:32:50Z","timestamp":1773667970000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1764722\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":26,"alternative-id":["10.3389\/fonc.2026.1764722"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1764722","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,16]]},"article-number":"1764722"}}